Recent studies have shown that standard treatment of heart failure may be augmented by inhibitors of sodium-glucose cotransporter 2 and glucagon-like peptide 1 analogues, both of whom may reduce cardiac mortality of DM patients in randomized, controlled trials [33–35]. The gene discussed is SLC5A2; the disease is diabetes mellitus.